Marc Pelletier

Company: Novartis AG

Job title: Associate Director, Translational Immune Oncology

Seminars:

Targeting NLRP3 in Myelodysplastic Syndrome: Initial Results from Phase Ib Trial of DFV890 9:00 am

Demonstrating NLRP3 pathway engagement through decreased systemic inflammatory cytokines and biomarker activity Evaluating the therapeutic potential of NLRP3 inhibition in earlier-stage MDS patients to enhance clinical response Investigating the link between inflammatory signaling and CHIP-associated mutationsRead more

day: Conference Day One AM